Research indicates that individuals with specific genetic variations related to appetite and digestion experience greater weight loss when using obesity medications such as Wegovy and Mounjaro. These drugs mimic a gut hormone that suppresses hunger. While genetics play a role, factors like sex, age, and geographical background also influence drug efficacy. In a study involving 15,000 participants, average weight loss was 11.7% over eight months, with some individuals losing up to 30%. Genetic analysis revealed a link between certain variants and weight loss outcomes.
"The study found a genetic variant associated with weight loss, which was also associated with nausea. People lose more weight if they have this variant."
"Drug trials suggest 14% weight loss on semaglutide (Ozempic and Wegovy) and 20% on tirzepatide (Mounjaro)."
"In this study, based on the experiences of 15,000 people taking weight-loss medications, they lost an average of 11.7% of their body weight during roughly eight months of treatment."
Read at www.bbc.com
Unable to calculate read time
Collection
[
|
...
]